Linda A Koehler1, David W Hunter2, Anne H Blaes3, Tufia C Haddad4. 1. Divisions of Physical Therapy and Rehabilitation Science, Department of Rehabilitation Medicine, University of Minnesota Medical School, Mayo Mail Code 388, 420 Delaware St. SE, Minneapolis, MN 55455; and Masonic Cancer Center, University of Minnesota. 2. Department of Radiology, University of Minnesota. 3. Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota; and Masonic Cancer Center, University of Minnesota. 4. Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota.
Abstract
Background: Axillary web syndrome (AWS) can develop following breast cancer surgery and presents as a tight band of tissue in the axilla with shoulder abduction. Objective: The objectives were to determine the prevalence and natural history of AWS and the association between AWS and function, range of motion, pain, lymphedema, and body mass index (BMI). Design: This study was a longitudinal prospective cohort study utilizing a repeated measures design. Methods: Axillary web syndrome, function, shoulder range of motion, pain, and lymphedema (using circumference, bioimpedance spectroscopy, tissue dielectric constant) were assessed in women at 2, 4, and 12 weeks and 18 months following breast cancer surgery. Prevalence of AWS and the association with the measured outcomes were analyzed. Results: Thirty-six women agreed to participate in the study. The cumulative prevalence of AWS was 50% (18/36) at 18 months following breast cancer surgery. AWS was identified as a risk factor for reduced function. Women with AWS had statistically reduced range of motion, lower BMI, and higher number of lymph nodes removed compared to the non-AWS group. Forty-one percent (13/32) of women had AWS at 18 months. AWS reoccurred in 6 women following resolution, and a new case developed beyond the early postoperative period. The overall prevalence of physical impairments ranged from 66% to 97% within the first 18 months following surgery regardless of AWS. Limitations: Limitations include a small sample size and potential treatment effect. Conclusion: AWS occurs in approximately 50% of women following breast cancer surgery. It can persist for 18 months and potentially longer, develop beyond the early postoperative time period, and reoccur after resolution. Clinicians need to be aware of the chronicity of AWS and its association with reduced range of motion and function.
Background: Axillary web syndrome (AWS) can develop following breast cancer surgery and presents as a tight band of tissue in the axilla with shoulder abduction. Objective: The objectives were to determine the prevalence and natural history of AWS and the association between AWS and function, range of motion, pain, lymphedema, and body mass index (BMI). Design: This study was a longitudinal prospective cohort study utilizing a repeated measures design. Methods:Axillary web syndrome, function, shoulder range of motion, pain, and lymphedema (using circumference, bioimpedance spectroscopy, tissue dielectric constant) were assessed in women at 2, 4, and 12 weeks and 18 months following breast cancer surgery. Prevalence of AWS and the association with the measured outcomes were analyzed. Results: Thirty-six women agreed to participate in the study. The cumulative prevalence of AWS was 50% (18/36) at 18 months following breast cancer surgery. AWS was identified as a risk factor for reduced function. Women with AWS had statistically reduced range of motion, lower BMI, and higher number of lymph nodes removed compared to the non-AWS group. Forty-one percent (13/32) of women had AWS at 18 months. AWS reoccurred in 6 women following resolution, and a new case developed beyond the early postoperative period. The overall prevalence of physical impairments ranged from 66% to 97% within the first 18 months following surgery regardless of AWS. Limitations: Limitations include a small sample size and potential treatment effect. Conclusion:AWS occurs in approximately 50% of women following breast cancer surgery. It can persist for 18 months and potentially longer, develop beyond the early postoperative time period, and reoccur after resolution. Clinicians need to be aware of the chronicity of AWS and its association with reduced range of motion and function.
Authors: Frank G Hunsaker; Dominic A Cioffi; Peter C Amadio; James G Wright; Beth Caughlin Journal: J Bone Joint Surg Am Date: 2002-02 Impact factor: 5.284
Authors: T Kuehn; W Klauss; M Darsow; S Regele; F Flock; C Maiterth; R Dahlbender; I Wendt; R Kreienberg Journal: Breast Cancer Res Treat Date: 2000-12 Impact factor: 4.872
Authors: Renate T de Jongh; Erik H Serné; Richard G IJzerman; Greetje de Vries; Coen D A Stehouwer Journal: Circulation Date: 2004-05-10 Impact factor: 29.690
Authors: Nancy K Janz; Mahasin Mujahid; Lynna K Chung; Paula M Lantz; Sarah T Hawley; Monica Morrow; Kendra Schwartz; Steven J Katz Journal: J Womens Health (Larchmt) Date: 2007-11 Impact factor: 2.681
Authors: Karol Ramírez-Parada; Diana Garay-Acevedo; Williams Mella-Abarca; Militza Petric-Guajardo; César Sánchez-Rojel; Margaret L McNeely; Ivana Leao-Ribeiro; Rodrigo Fernández-Verdejo Journal: Support Care Cancer Date: 2019-11-25 Impact factor: 3.603
Authors: Cheryl L Brunelle; Sacha A Roberts; Amy M Shui; Tessa C Gillespie; Kayla M Daniell; George E Naoum; Alphonse Taghian Journal: J Surg Oncol Date: 2020-06-04 Impact factor: 3.454
Authors: Linda Koehler; Amanda Day; David Hunter; Anne Blaes; Tufia Haddad; Ryan Shanley Journal: Arch Phys Med Rehabil Date: 2022-04-06 Impact factor: 4.060
Authors: Elizabeth A Chrischilles; Danielle Riley; Elena Letuchy; Linda Koehler; Joan Neuner; Cheryl Jernigan; Brian Gryzlak; Neil Segal; Bradley McDowell; Brian Smith; Sonia L Sugg; Jane M Armer; Ingrid M Lizarraga Journal: Breast Cancer Res Treat Date: 2019-03-09 Impact factor: 4.872
Authors: María Jesús Muñoz-Fernández; Esther M Medrano-Sánchez; Beatriz Ostos-Díaz; Rocío Martín-Valero; Carmen Suárez-Serrano; María Jesús Casuso-Holgado Journal: Int J Environ Res Public Health Date: 2021-01-31 Impact factor: 3.390
Authors: Kim Michéle Feder; Hans Bjarke Rahr; Marianne Djernes Lautrup; Heidi Klakk Egebæk; Robin Christensen; Kim Gordon Ingwersen Journal: Trials Date: 2022-08-20 Impact factor: 2.728
Authors: Chirag Shah; April Zambelli-Weiner; Nicole Delgado; Ashley Sier; Robert Bauserman; Jerrod Nelms Journal: Breast Cancer Res Treat Date: 2020-11-27 Impact factor: 4.872